Synthesis, Type II diabetes inhibitory activity, antimicrobial evaluation and docking studies of indeno[1,2-c]pyrazol-4(1H)-ones
- 26 Downloads
We report a convenient and efficient synthesis of indeno[1,2-c]pyrazol-4(1H)-ones (4a‒o) by the reaction of a variety of 2-acyl-(1H)-indene-1,3(2H)-diones (1) and 2-hydrazinylbenzo[d]thiazole/2-hydrazinyl-6-substitutedbenzo[d]thiazoles (2) in the presence of glacial acetic acid in good yields. The structure of the compounds thus prepared were confirmed by analytical and spectral (FT-IR, 1H NMR, 13C NMR, and HRMS) techniques. All the synthesized indeno[1,2-c]pyrazol-4(1H)-ones (4a‒o) were assayed for their in vitro Type II diabetes inhibitory activity by using Acarbose as standard drug and in vitro antimicrobial activity utilizing Streptomycin and Fluconazole as reference drugs. Among the synthesized derivatives, 4e (IC50 = 6.71 μg/mL) was found to be more potent against α-glucosidase enzyme as compared with the standard Acarbose (IC50 = 9.35 μg/mL) and 4i (IC50 = 11.90 μg/mL) exhibited good inhibitory activity against α-amylase enzyme as compared with the standard Acarbose (IC50 = 22.87 μg/mL). Also, all the titled compounds showed good antimicrobial activity. In addition, in vitro α-glucosidase and α-amylase inhibition were supported by docking studies performed on the derivatives 4e and 4o, respectively.
KeywordsIndeno[1,2-c]pyrazol-4(1H)-ones α-Glucosidase α-Amylase Antibacterial Antifungal Molecular docking
The authors are grateful to the Council of Scientific and Industrial Research, New Delhi, India for providing financial support (CSIR No. 09/752(0060)/2016-EMR-I).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- Ahsan MJ, Govindasamy J, Khalilullah H, Mohan G, Stables JP, Pannecouque C, De Clercq E (2012) POMA analyses as new efficient bioinformatics platform to predict and optimise bioactivity of synthesized 3a,4-dihydro-3H-indeno[1,2-c]pyrazole-2-carboxamide/carbothioamide analogues. Bioorg Med Chem Lett 22(23):7029–7035PubMedCrossRefPubMedCentralGoogle Scholar
- International Diabetes Foundation (2017) IDF diabetes atlas. 8th ed. International Diabetes Foundation, BrusselsGoogle Scholar
- Khan I, Garikapati KR, Setti A, Shaik AB, Makani VKK, Shareef MA, Kumar CG (2019) Design, synthesis, in silico pharmacokinetics prediction and biological evaluation of 1,4-dihydroindeno[1,2-c]pyrazole chalcone as EGFR/Akt pathway inhibitors. Eur J Med Chem 163:636–648PubMedCrossRefPubMedCentralGoogle Scholar
- Minegishi H, Futamura Y, Fukashiro S, Muroi M, Kawatani M, Osada H, Nakamura H (2015) Methyl 3-((6-methoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-yl)amino) benzoate (GN39482) as a tubulin polymerization inhibitor identified by MorphoBase and ChemProteoBase profiling methods. J Med Chem 58(10):4230–4241PubMedCrossRefPubMedCentralGoogle Scholar
- Mor S, Sindhu S, Nagoria S, Khatri M, Garg P, Sandhu H, Kumar A (2019) Synthesis, biological evaluation, and molecular docking studies of some N‐thiazolyl hydrazones and indenopyrazolones. J Heterocycl Chem 56(5):1622–1633Google Scholar
- Mor S, Sindhu S, Khatri M, Singh N, Vasudeva N, Panihar N (2019) Synthesis, type II Diabetes inhibitory activity, and antimicrobial tests of benzothiazole derivatives bridged with indenedione by methylenehydrazone. Russ J Gen Chem 89(9):1867–1873Google Scholar
- Sarkar S, Dwivedi J, Chauhan R (2013) Synthesis of 1-[2(substituted phenyl)-4-oxothiazolidin-3-yl]-3-(6-fluro-7-chloro-1,3-benzothiazol-2-yl)-ureas as anthelmintic agent. J Pharm Res 7(5):439–442Google Scholar
- Shareef MA, Sirisha K, Khan I, Sayeed IB, Jadav SS, Ramu G, Babu BN (2019) Design, synthesis, and antimicrobial evaluation of 1,4-dihydroindeno[1,2-c]pyrazole tethered carbohydrazide hybrids: exploring their in silico ADMET, ergosterol inhibition and ROS inducing potential. Med Chem Comm 10(5):806–813CrossRefGoogle Scholar
- Wagman AS, Boyce RS, Brown SP, Fang E, Goff D, Jansen JM, Nuss JM (2017) Synthesis, binding mode, and antihyperglycemic activity of potent and selective (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl] amine inhibitors of glycogen synthase kinase 3. J Med Chem 60(20):8482–8514PubMedCrossRefPubMedCentralGoogle Scholar
- Yevich JP, New JS, Smith DW, Lobeck WG, Catt JD, Minielli JL, Temple Jr. DL (1986) Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl) and (1,2-benzisoxazol-3-yl) piperazine derivatives as potential antipsychotic agents. J Med Chem 29(3):359–369PubMedCrossRefPubMedCentralGoogle Scholar